ES2624241T3 - Anticuerpo para el receptor de tirotropina y sus usos - Google Patents
Anticuerpo para el receptor de tirotropina y sus usos Download PDFInfo
- Publication number
- ES2624241T3 ES2624241T3 ES10184462.9T ES10184462T ES2624241T3 ES 2624241 T3 ES2624241 T3 ES 2624241T3 ES 10184462 T ES10184462 T ES 10184462T ES 2624241 T3 ES2624241 T3 ES 2624241T3
- Authority
- ES
- Spain
- Prior art keywords
- tsh receptor
- tsh
- binding
- molecule
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000015486 thyroid-stimulating hormone receptor activity proteins Human genes 0.000 title description 8
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 title description 8
- 230000027455 binding Effects 0.000 claims abstract description 606
- 102000003911 Thyrotropin Receptors Human genes 0.000 claims abstract description 558
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims abstract description 558
- 239000012634 fragment Substances 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 86
- 230000003993 interaction Effects 0.000 claims abstract description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 210000001124 body fluid Anatomy 0.000 claims abstract description 31
- 239000010839 body fluid Substances 0.000 claims abstract description 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 25
- 229920001184 polypeptide Polymers 0.000 claims abstract description 24
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 22
- 230000008105 immune reaction Effects 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 115
- 238000012360 testing method Methods 0.000 claims description 96
- 230000000694 effects Effects 0.000 claims description 44
- 238000004519 manufacturing process Methods 0.000 claims description 42
- 230000004936 stimulating effect Effects 0.000 claims description 42
- 239000003446 ligand Substances 0.000 claims description 28
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 abstract description 30
- 108020003175 receptors Proteins 0.000 abstract description 30
- 108010061174 Thyrotropin Proteins 0.000 description 186
- 102000011923 Thyrotropin Human genes 0.000 description 186
- 239000000523 sample Substances 0.000 description 112
- 210000002966 serum Anatomy 0.000 description 79
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 68
- 230000005764 inhibitory process Effects 0.000 description 67
- 102100029337 Thyrotropin receptor Human genes 0.000 description 66
- 125000003275 alpha amino acid group Chemical group 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 45
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 41
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 41
- 229940095074 cyclic amp Drugs 0.000 description 41
- 238000003556 assay Methods 0.000 description 40
- 230000000638 stimulation Effects 0.000 description 36
- 210000004698 lymphocyte Anatomy 0.000 description 32
- 239000002773 nucleotide Substances 0.000 description 32
- 125000003729 nucleotide group Chemical group 0.000 description 32
- 210000001685 thyroid gland Anatomy 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 239000012228 culture supernatant Substances 0.000 description 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 20
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 20
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000001276 controlling effect Effects 0.000 description 16
- 108091033319 polynucleotide Chemical group 0.000 description 16
- 239000002157 polynucleotide Chemical group 0.000 description 16
- 102000040430 polynucleotide Human genes 0.000 description 16
- 208000015023 Graves' disease Diseases 0.000 description 15
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 15
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 208000023328 Basedow disease Diseases 0.000 description 14
- 229960002685 biotin Drugs 0.000 description 14
- 239000011616 biotin Substances 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000013615 primer Substances 0.000 description 14
- 108010032595 Antibody Binding Sites Proteins 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 235000020958 biotin Nutrition 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 230000005784 autoimmunity Effects 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 229960000874 thyrotropin Drugs 0.000 description 7
- 230000001748 thyrotropin Effects 0.000 description 7
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000003491 cAMP production Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- -1 aliphatic amino acids Chemical class 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000012898 sample dilution Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 4
- 101000873786 Homo sapiens Glutamate decarboxylase 2 Proteins 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 208000026062 Tissue disease Diseases 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000010807 negative regulation of binding Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229940036555 thyroid hormone Drugs 0.000 description 4
- 239000005495 thyroid hormone Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102000014169 Steroid 21-Hydroxylase Human genes 0.000 description 3
- 108010011732 Steroid 21-Hydroxylase Proteins 0.000 description 3
- 102000009843 Thyroglobulin Human genes 0.000 description 3
- 108010034949 Thyroglobulin Proteins 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000037011 constitutive activity Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000013391 scatchard analysis Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960002175 thyroglobulin Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MZIYRTZAYQIAHW-UHFFFAOYSA-N 1-methyl-8-(2-methylpropyl)-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)N(C)C(=O)C2=C1N=C(CC(C)C)N2 MZIYRTZAYQIAHW-UHFFFAOYSA-N 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101710170230 Antimicrobial peptide 1 Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010036012 Iodide peroxidase Proteins 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102000014267 Thyroid peroxidases Human genes 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000012656 cationic ring opening polymerization Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003202 long acting thyroid stimulator Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HKAVADYDPYUPRD-UHFFFAOYSA-N 1h-pyrazine-2-thione Chemical compound SC1=CN=CC=N1 HKAVADYDPYUPRD-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 238000012232 AGPC extraction Methods 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101150009575 RH10 gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102100027188 Thyroid peroxidase Human genes 0.000 description 1
- 108010066702 Thyrotropin Alfa Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- YDMCWONVABEGBK-UHFFFAOYSA-N carbamimidoylazanium;phenoxide Chemical compound NC(N)=N.OC1=CC=CC=C1 YDMCWONVABEGBK-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0227964 | 2002-11-29 | ||
| GBGB0227964.4A GB0227964D0 (en) | 2002-11-29 | 2002-11-29 | Binding partners for the thyrotropin receptor and uses thereof |
| GBGB0302140.9A GB0302140D0 (en) | 2002-11-29 | 2003-01-29 | Binding partners for the thyrotropin receptor and uses thereof |
| GB0302140 | 2003-01-29 | ||
| GB0315147A GB0315147D0 (en) | 2002-11-29 | 2003-06-27 | Binding partners for the thyrotropin receptor and uses thereof |
| GB0315147 | 2003-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2624241T3 true ES2624241T3 (es) | 2017-07-13 |
Family
ID=9948838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03778537T Expired - Lifetime ES2371244T3 (es) | 2002-11-29 | 2003-11-28 | Anticuerpo para el receptor de tirotropina y usos del mismo. |
| ES10184462.9T Expired - Lifetime ES2624241T3 (es) | 2002-11-29 | 2003-11-28 | Anticuerpo para el receptor de tirotropina y sus usos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03778537T Expired - Lifetime ES2371244T3 (es) | 2002-11-29 | 2003-11-28 | Anticuerpo para el receptor de tirotropina y usos del mismo. |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP5722927B2 (enExample) |
| AT (1) | ATE525086T1 (enExample) |
| ES (2) | ES2371244T3 (enExample) |
| GB (2) | GB0227964D0 (enExample) |
| HU (1) | HUE034370T2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5304939B1 (ja) * | 2012-05-31 | 2013-10-02 | 大日本印刷株式会社 | 光学積層体、偏光板、偏光板の製造方法、画像表示装置、画像表示装置の製造方法及び画像表示装置の視認性改善方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9909661D0 (en) * | 1998-06-06 | 1999-06-23 | Rsr Ltd | Assays for TSH receptor autoantibodies |
| JP5314234B2 (ja) * | 2002-11-29 | 2013-10-16 | アールエスアール リミテッド | チロトロピン受容体の結合対象及びその使用 |
-
2002
- 2002-11-29 GB GBGB0227964.4A patent/GB0227964D0/en not_active Ceased
-
2003
- 2003-01-29 GB GBGB0302140.9A patent/GB0302140D0/en not_active Ceased
- 2003-11-28 AT AT03778537T patent/ATE525086T1/de active
- 2003-11-28 ES ES03778537T patent/ES2371244T3/es not_active Expired - Lifetime
- 2003-11-28 ES ES10184462.9T patent/ES2624241T3/es not_active Expired - Lifetime
- 2003-11-28 HU HUE10184462A patent/HUE034370T2/en unknown
-
2013
- 2013-01-18 JP JP2013007593A patent/JP5722927B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2371244T3 (es) | 2011-12-28 |
| HUE034370T2 (en) | 2018-02-28 |
| JP5722927B2 (ja) | 2015-05-27 |
| GB0227964D0 (en) | 2003-01-08 |
| ATE525086T1 (de) | 2011-10-15 |
| JP2013126987A (ja) | 2013-06-27 |
| GB0302140D0 (en) | 2003-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8753637B2 (en) | Binding partners for the thyrotropin receptor and uses thereof | |
| CN112250763B (zh) | 靶向SARS-CoV-2冠状病毒的抗体及其诊断和检测用途 | |
| CN101048659B (zh) | 抗前胃泌素单克隆抗体 | |
| JP7215759B2 (ja) | ４－１ｂｂ抗体およびその製造方法と使用 | |
| EP3766901A1 (en) | Antibody targeting ctla-4 , preparation method therefor and use thereof | |
| JP6400480B2 (ja) | ペプチドグリカン認識タンパク質１に結合する抗体 | |
| AU2021250840B2 (en) | Compositions and methods for detecting and treating ovarian cancer | |
| CN109988240B (zh) | 抗gpc-3抗体及其用途 | |
| PT2328931E (pt) | Anticorpos selectivos anti-hepcidina-25 e utilizações dos mesmos | |
| CN106573972B (zh) | 交联B淋巴细胞的CD23但不致敏肥大细胞的人源化抗-IgE抗体 | |
| KR20180108586A (ko) | 식도암을 검출 및 치료하기 위한 조성물 및 방법 | |
| Sanders et al. | Characteristics of a monoclonal antibody to the thyrotropin receptor that acts as a powerful thyroid-stimulating autoantibody antagonist | |
| JP2011097869A (ja) | 抗ヒトアデノシンＡ２ａ受容体モノクローナル抗体 | |
| ES2753400T3 (es) | Nuevo anticuerpo anti-presepsina | |
| JP2729159B2 (ja) | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 | |
| CA3193501A1 (en) | Compositions and methods for detecting and treating gastric cancer | |
| CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| CN117242092A (zh) | Vegfa结合分子 | |
| ES2624241T3 (es) | Anticuerpo para el receptor de tirotropina y sus usos | |
| KR20220092859A (ko) | 항-cxcr2 항체 및 이의 용도 | |
| US7517663B2 (en) | Rabbit monoclonal antibody against Id1 protein | |
| Su et al. | Production and characterization of monoclonal antibodies against the vasoconstrictive peptide human urotensin-II |